130 related articles for article (PubMed ID: 3208019)
1. Relapse of osteoporosis circumscripta as a lytic ring after treatment of Paget's disease with intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate.
Anderson DC; O'Driscoll JB; Buckler HM; Cantrill J; Brown JD
Br J Radiol; 1988 Nov; 61(731):996-1001. PubMed ID: 3208019
[TBL] [Abstract][Full Text] [Related]
2. Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD.
Dodd GW; Ibbertson HK; Fraser TR; Holdaway IM; Wattie D
Br J Radiol; 1987 Sep; 60(717):849-60. PubMed ID: 3117159
[TBL] [Abstract][Full Text] [Related]
3. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.
Cantrill JA; Buckler HM; Anderson DC
Ann Rheum Dis; 1986 Dec; 45(12):1012-8. PubMed ID: 3813665
[TBL] [Abstract][Full Text] [Related]
4. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
5. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
[TBL] [Abstract][Full Text] [Related]
6. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
[TBL] [Abstract][Full Text] [Related]
7. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
Chapurlat R; Meunier PJ
Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Oostendorp-van de Ruit M; Van der Pluijm G; Löwik CW; Papapoulos SE
J Bone Miner Res; 1995 Jun; 10(6):956-62. PubMed ID: 7572320
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone.
Heynen G; Delwaide P; Bijvoet OL; Franchimont P
Eur J Clin Invest; 1982 Feb; 12(1):29-35. PubMed ID: 6802650
[No Abstract] [Full Text] [Related]
10. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
11. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
Chakravarty K; Merry P; Scott DG
J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
[TBL] [Abstract][Full Text] [Related]
12. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate.
Papapoulos SE; Hoekman K; Löwik CW; Vermeij P; Bijvoet OL
J Bone Miner Res; 1989 Oct; 4(5):775-81. PubMed ID: 2816519
[TBL] [Abstract][Full Text] [Related]
13. Quantitative bone scintigraphy in Paget's disease treated with APD.
Vellenga CJ; Pauwels EK; Bijvoet OL; Harinck HI; Frijlink WB
Br J Radiol; 1985 Dec; 58(696):1165-72. PubMed ID: 3842627
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid for Paget's disease of bone.
Maricic M
Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
[TBL] [Abstract][Full Text] [Related]
16. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
17. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone.
Reid IR; Wattie D; Gamble GD; Kalluru R; Cundy T
Calcif Tissue Int; 2017 Mar; 100(3):250-254. PubMed ID: 27866237
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
